These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
625 related articles for article (PubMed ID: 21610128)
41. An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein. Seijsing J; Lindborg M; Höidén-Guthenberg I; Bönisch H; Guneriusson E; Frejd FY; Abrahmsén L; Ekblad C; Löfblom J; Uhlén M; Gräslund T Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17110-5. PubMed ID: 25406323 [TBL] [Abstract][Full Text] [Related]
42. Binding parameters and idiotypic profile of the whole immunoglobulin and Fab' fragments of murine monoclonal antibody to distinct determinants of the human high molecular weight-melanoma associated antigen. Temponi M; Gold AM; Ferrone S Cancer Res; 1992 May; 52(9):2497-503. PubMed ID: 1373670 [TBL] [Abstract][Full Text] [Related]
43. Stoichiometry of the interaction between the major histocompatibility complex-related Fc receptor and its Fc ligand. Sánchez LM; Penny DM; Bjorkman PJ Biochemistry; 1999 Jul; 38(29):9471-6. PubMed ID: 10413524 [TBL] [Abstract][Full Text] [Related]
44. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering. Wang Y; Tian Z; Thirumalai D; Zhang X J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896 [TBL] [Abstract][Full Text] [Related]
45. In Translation: FcRn across the Therapeutic Spectrum. Qi T; Cao Y Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802650 [TBL] [Abstract][Full Text] [Related]
46. Engineered FcRn Binding Fusion Peptides Significantly Enhance the Half-Life of a Fab Domain in Cynomolgus Monkeys. Datta-Mannan A; Boyles J; Huang L; Jin ZY; Peariso A; Murphy AT; Ellis B; Douglass N; Norouziyan-Cooper F; Witcher DR Biotechnol J; 2019 Mar; 14(3):e1800007. PubMed ID: 29802766 [TBL] [Abstract][Full Text] [Related]
47. Identification of critical IgG binding epitopes on the neonatal Fc receptor. Vaughn DE; Milburn CM; Penny DM; Martin WL; Johnson JL; Bjorkman PJ J Mol Biol; 1997 Dec; 274(4):597-607. PubMed ID: 9417938 [TBL] [Abstract][Full Text] [Related]
48. Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody. Haraya K; Tachibana T; Nanami M; Ishigai M Xenobiotica; 2014 Dec; 44(12):1127-34. PubMed ID: 25030041 [TBL] [Abstract][Full Text] [Related]
49. Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells. Goebl NA; Babbey CM; Datta-Mannan A; Witcher DR; Wroblewski VJ; Dunn KW Mol Biol Cell; 2008 Dec; 19(12):5490-505. PubMed ID: 18843053 [TBL] [Abstract][Full Text] [Related]
50. A strategy for bacterial production of a soluble functional human neonatal Fc receptor. Andersen JT; Justesen S; Berntzen G; Michaelsen TE; Lauvrak V; Fleckenstein B; Buus S; Sandlie I J Immunol Methods; 2008 Feb; 331(1-2):39-49. PubMed ID: 18155020 [TBL] [Abstract][Full Text] [Related]
51. Monoclonal Antibody Engineering and Design to Modulate FcRn Activities: A Comprehensive Review. Ramdani Y; Lamamy J; Watier H; Gouilleux-Gruart V Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077002 [TBL] [Abstract][Full Text] [Related]
52. Methods for Functional Characterization of FcRn Interactions with Therapeutic Antibodies and Fc-Fusion Proteins. Chung S; Lin YL; Nguyen V; Liu C Methods Mol Biol; 2022; 2313():295-303. PubMed ID: 34478146 [TBL] [Abstract][Full Text] [Related]
53. High-affinity binding of the neonatal Fc receptor to its IgG ligand requires receptor immobilization. Vaughn DE; Bjorkman PJ Biochemistry; 1997 Aug; 36(31):9374-80. PubMed ID: 9235980 [TBL] [Abstract][Full Text] [Related]
54. FcRn-mediated transcytosis of immunoglobulin G in human renal proximal tubular epithelial cells. Kobayashi N; Suzuki Y; Tsuge T; Okumura K; Ra C; Tomino Y Am J Physiol Renal Physiol; 2002 Feb; 282(2):F358-65. PubMed ID: 11788451 [TBL] [Abstract][Full Text] [Related]
55. Characterization of the interactions of rabbit neonatal Fc receptor (FcRn) with rabbit and human IgG isotypes. Szikora B; Hiripi L; Bender B; Kacskovics I; Iliás A PLoS One; 2017; 12(9):e0185662. PubMed ID: 28957416 [TBL] [Abstract][Full Text] [Related]
56. Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors. Goulet DR; Zwolak A; Williams JA; Chiu ML; Atkins WM Proteins; 2020 May; 88(5):689-697. PubMed ID: 31702857 [TBL] [Abstract][Full Text] [Related]
57. Quantitative methods for developing Fc mutants with extended half-lives. Kamei DT; Lao BJ; Ricci MS; Deshpande R; Xu H; Tidor B; Lauffenburger DA Biotechnol Bioeng; 2005 Dec; 92(6):748-60. PubMed ID: 16136591 [TBL] [Abstract][Full Text] [Related]
58. Effect of individual Fc methionine oxidation on FcRn binding: Met252 oxidation impairs FcRn binding more profoundly than Met428 oxidation. Gao X; Ji JA; Veeravalli K; Wang YJ; Zhang T; Mcgreevy W; Zheng K; Kelley RF; Laird MW; Liu J; Cromwell M J Pharm Sci; 2015 Feb; 104(2):368-77. PubMed ID: 25175600 [TBL] [Abstract][Full Text] [Related]
59. Structure-activity relationships of a peptide inhibitor of the human FcRn:human IgG interaction. Mezo AR; McDonnell KA; Castro A; Fraley C Bioorg Med Chem; 2008 Jun; 16(12):6394-405. PubMed ID: 18501614 [TBL] [Abstract][Full Text] [Related]